drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified T cells engineered to express an anti-CD7 chimeric antigen receptor with costimulatory and CD3ΞΆ signaling domains; administered as a single infusion to redirect T-cell cytotoxicity against CD7+ malignant T cells in r/r T-ALL/T-LBL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD7-specific chimeric antigen receptor with costimulatory and CD3z signaling domains. CAR engagement of CD7 on malignant T cells activates the engineered T cells to proliferate, secrete cytokines, and kill CD7+ targets via perforin/granzyme-mediated cytotoxicity in r/r T-ALL/T-LBL.
drug_name
RD13-02 (anti-CD7 CAR T-cell therapy)
nct_id_drug_ref
NCT05902845